INTRODUCTION
Primary mediastinal B-cell lymphoma (PMBL) is recognized as a separate entity of aggressive B-cell lymphoma, with unique clinical, histological, and biologic features. This lymphoma presents as a mediastinal mass consisting of large B cells, that usually express little if 1 any surface or cytoplasmic immunoglobulin and major histocompatibility complex class I and/or class II molecules and presumably derive from a subset of thymic B cells. PMBL displays a constitutive activation of the JAK/STAT signaling pathway as indicated by the 2 presence of nuclear phosphorylated (P) STAT6, which is also observed in Hodgkin lymphoma. , STAT6 expression was shown to 3 4 5 regulate cell proliferation and survival in a PMBL derived cell line, MedB-1. These lymphomas harbor chromosomal gains of the 6 JAK2
gene, and inactivating mutations of the Suppressor of Cytokine Signaling ( gene, which are also commonly found in Hodgkin 7 SOCS) 1 8 lymphoma. , Although SOCS1 inactivation prevents STAT6 downregulation and thereby contributes to STAT6 activity, the primary 9 10 6 mechanism responsible for STAT6 activation remains unclear. PMBL do not secrete the specific cytokines (i.e., Interleukin -4 or - 13) classically involved in the activation of this factor, unlike classical Hodgkin lymphoma , and JAK2 inhibition only partially prevented 11 12 STAT6 activation in MedB-1.3
The analysis of STAT6 functional properties by directed mutagenesis has shown that a mutation in the SH2 domain (STAT6 V547A/T548A) leads to the constitutive activation of STAT6. This mutation changes the conformation of the protein and increases the 13 stability of the monomeric and dimeric proteins, allowing STAT6VT mutant protein to undergo tyrosine phosphorylation, followed by sections. Total RNA were extracted from frozen tissue samples with TRIZOL reagent (Invitrogen, Cergy Pontoise, France) or Qiagen RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer s instructions. Genomic DNA was extracted with proteinase K ' digestion, phenol chloroform phases separation and ethanol precipitation.
MATERIAL AND METHODS

Sequencing and quantitative Polymerase Chain Reaction (PCR)
Total RNA were reverse transcribed with Superscript II (Invitrogen, San Diego, CA) and poly-dT (500 ng) or random (300 ng) primers in a final volume of 20 l, according to the manufacturer s instructions, and diluted 1:5 or 1:10 for PCR. Genomic DNA and cDNA were Germany) was added to the medium and HEK293 cells were cultured in the selection medium for 2 weeks before isolation of single clones or pooling transfected cells. During analysis, the transfected cells were maintained under 600 g/ml of G418. Western blots were performed as previously described. Proteins were detected using antibodies against STAT6 (M-200; sc-1698) 6
(Santa Cruz) 1:1000; P-STAT6 (Tyr641; 9361) (Cell Signaling, Beverly, MA) 1:1000; beta actin (clone AC-74), (Sigma-Aldrich, Saint Louis, MO) 1:5000; HDAC1 (H-51) (Santa Cruz) 1:1000. 
RESULTS
Recurrent mutations of STAT6 DNA binding domain in MedB-1 cell line and PMBL primary tumors
We analyzed the entire coding sequence of mRNA in MedB-1 and Karpas1106 PMBL derived cell lines. Direct sequencing of STAT6 PCR products showed that Karpas1106 cells carried wild type (WT) mRNA sequences, whereas MedB-1 cells exhibited two STAT6 heterozygous missense mutations located in exon 12 (N417Y and N430T), which encodes part of the DNA binding domain. We amplified MedB-1 exon 12 genomic DNA and sequenced cloned PCR products. Seven clones showed both N417Y and N430T mutations and two were WT, indicating that both mutations were located on the same allele. These mutations were detected in the parental tumor from which this cell line was established, but were absent in fibroblasts isolated from the same patient. 22
To evaluate the relevance of these mutations in PMBL, we sequenced the region of the gene encoding amino-acids L406 to STAT6 test, <0,0002). Interestingly, six PMBL cases had several missense mutations and one case had both a missense and a silent mutation ( p ). The 28 mutations that we detected were heterozygous and targeted preferentially A:T base pairs (20/28, exact binomial test, Figure 1a p 0,0035) and AA, AG, AT or GA dinucleotides ( ). These mutations mostly affected exon 12, with four hotspots targeting amino = Table 1 acid 417, 419, 421 and 430, respectively ( ). Of note, D419 is the site of a known polymorphism (D419N), which was not Figure 1b ). Twelve PMBL cases previously shown to have a PMBL molecular signature, had Out
Functional properties of STAT6 mutant proteins
In order to evaluate the functional properties of the mutated STAT6 proteins, we transfected the HEK293 STAT6 deficient cell line with expression vectors encoding either WT or N417/N430 double mutant (DM) STAT6, expressed in MedB-1/parental tumor and case 52. Independent stable pools and clones exhibited the same levels of basal and interleukin-4 (IL-4) induced STAT6 phosphorylation (
). DM STAT6 transfectants showed a decreased DNA binding activity on both N4 and N3 GAS sites (TTC N xGAA), compared Figure 2a [ ] to WT STAT6 expressing cells, although similar amounts of STAT6 and P-STAT6 were detected in the nucleus of WT and DM STAT6 expressing cells ( ). We hypothesized that the diminished DNA binding activity of STAT6 mutants might affect their ability to Figure 2b activate the expression of N4-or N3-GAS driven reporters. As shown in , HEK293 cells transiently transfected with double Figure 2c mutant or with N417Y, D419H, N421K, N430T STAT6 single mutants displayed reduced N4-and N3-sites driven reporter expression, compared to WT STAT6 expressing cells, although achieving similar levels of P-STAT6 after IL-4 stimulation.
The decreased ability of STAT6 mutants to activate transcription was surprising considering the strong STAT6 signature previously reported in gene expression profiling studies of PMBL. , We therefore compared the levels of expression of several genes which 19 23
contain confirmed STAT6 binding motifs in the 5 non-mutated and the 7 mutated cases which had been analyzed with microarrays as 26 part of a larger study. The levels of expression of these genes were similar in the two groups ( ), indicating that these mutations 19 Table 3 did not significantly impair the expression of these endogenous STAT6 targets in lymphoma cells. these mutations affect tumor growth remain elusive. Although STAT6 mutants showed an impaired function on short synthetic promoters in a heterologous cell system, PMBL samples did not show a decreased expression of classical STAT6 targets. This apparent discrepancy may be due to the fact that the highly complex transcriptional regulation coordinated by STAT6 is not addressed in HEK cells in vivo * Expected mutation frequencies were calculated according to the sequence composition, assuming random targeting of the mutations at a 28/365 rate for single nucleotide changes and 56/364 rate for dinucleotide mutations. °S tatistical comparisons were done with the exact binomial test, which compares the observed frequency to the expected one under null hypothesis. The dinucleotides which were significantly targeted by mutations are highlighted in bold. 
